Michael Severino, Tessera Therapeutics CEO
After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline
A secretive biotech startup developing a new form of gene editing is starting to give curious scientists a peek at its pipeline — without fully divulging how its closely scrutinized technology works.
On Friday, Tessera Therapeutics announced preliminary data from five preclinical programs using its “gene writers” to tweak specific letters or insert entirely new sequences of DNA. The techniques are part of a larger movement in the gene editing field to develop tools that could treat nearly any conceivable genetic disease, and Tessera is one of its top contenders.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters